![We present a 64-year-old man with subacute left-side dominant bilateral choreic movement (diabetic chorea) evaluated using a combination of dopamine transporter SPECT, ^18^F FDG PET, ^99m^Tc ethylcysteinate dimer (^99m^Tc ECD) SPECT, and ^123^I metaiodobenzylguanidine (MIBG) scintigraphy. We diagnosed him with diabetic chorea because of poorly controlled diabetes mellitus (HbA1c 13%-18%) and brain MRI showing pathognomonic hyperintensity on T1-weighted imaging in the bilateral caudate nucleus and putamen and right-side external segment of the globus pallidus (**A**). No significant abnormality on T2- (**B**) and T2\*-weighted images (**C**) was found in the corresponding area. No significant old infarction or other differential diagnoses for chorea were identified.^[@R1]^ Dopamine transporter SPECT showed bilaterally and right-side dominant reduced ^123^I ioflupane binding in the caudate nucleus and putamen (**D**). The specific binding ratio^[@R2]^ was 1.22 on the right and 1.36 on the left side (ELEGP was used as a collimator, and no scatter correction or attenuation correction was applied). The asymmetry dopamine transporter SPECT in diabetic chorea index (AI) of ioflupane binding was 10.7%, revealing a decline predominantly on the right side. This was consistent with the contralateral dominance of the chorea. No confounding medication for the evaluation with dopamine transporter SPECT was identified.^[@R3]^ Brain ^18^F FDG PET revealed decreased glucose metabolism (**E**) in the corresponding area, similar to the dopamine transporter SPECT, suggesting regional dysfunction in the bilateral striatum. There was no significant left-to-right difference in striatal ^18^F FDG PET uptake, with an AI of 2.7%. ^99m^Tc ECD SPECT revealed reduced brain perfusion in the bilateral caudate nucleus, putamen, and thalamus (**F**). ^123^I MIBG scintigraphy showed no reduction in the H/M ratio, with 4.95 in the early phase and 5.03 in the late phase (**G**, late phase). We assumed that a low accumulation in the mediastinum caused this high H/M ratio. Treatment with dopamine antagonist and blood glucose control relieved most choreic symptoms within 4 weeks, and we are now successfully reducing his dopamine antagonist dose. Reduced glucose metabolism was found in the bilateral putamen and caudate nucleus in the ^18^F FDG PET in our patient, suggesting regional striatal dysfunction. This was consistent with earlier studies on diabetic chorea.^[@R4]--[@R7]^ Several theories regarding the underlying pathology of diabetic chorea have been proposed, including petechial hemorrhage,^[@R7]^ metabolic abnormality because of hyperglycemia,^[@R5],[@R7]^ patchy striatal necrosis associated with vasculopathy,^[@R6]^ and transient ischemia.^[@R7]^ No conclusion has been reached to date. The only earlier report using dopamine transporter SPECT with hyperglycemic hemichorea-hemiballismus^[@R8]^ revealed decreased ^123^I ioflupane binding in the striatum as was observed in our case. Cardiac imaging with ^123^I MIBG scintigraphy in our case revealed normal ^123^I MIBG uptake by the cardiac sympathetic nerve, suggesting that coexisting Parkinson's disease, Lewy body disease, diabetic sympathetic nerve dysfunction, or heart failure were unlikely. This suggests nigrostriatal dopaminergic involvement: presynaptic neuronal terminal dysfunction, reduced density of nerve terminals, or reduced density of dopamine transporter is conceivable.^[@R8],[@R9]^](rlu-41-481-g001){#FU1}
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